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Neurobiology of Disease
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Modification of arginine residues by citrullination is catalyzed by peptidylarginine deiminases (PADs), of which five are known, gener-
ating irreversible protein structural modifications. We have shown previously that enhanced citrullination of myelin basic protein
contributed to destabilization of the myelin membrane in the CNS of multiple sclerosis (MS) patients. We now report increased citrulli-
nation of nucleosomal histones by PAD4 in normal-appearing white matter (NAWM) of MS patients and in animal models of demyeli-
nation. Histone citrullination was attributable to increased levels and activity of nuclear PAD4. PAD4 translocation into the nucleus was
attributable to elevated tumor necrosis factor- (TNF-) protein. The elevated TNF- in MS NAWM was not associated with CD3 or
CD8 lymphocytes, norwas it associatedwith CD68microglia/macrophages. GFAP, ameasure of astrocytosis, was the only cytological
marker that was consistently elevated in the MS NAWM, suggesting that TNF-may have been derived from astrocytes. In cell cultures
of mouse and human oligodendroglial cell lines, PAD4was predominantly cytosolic but TNF- treatment induced its nuclear transloca-
tion. To address the involvement of TNF- in targeting PAD4 to the nucleus, we found that transgenic mice overexpressing TNF- also
had increased levels of citrullinated histones and elevated nuclear PAD4 before demyelination. In conclusion, high citrullination of
histones consequent to PAD4 nuclear translocation is part of the process that leads to irreversible changes in oligodendrocytes andmay
contribute to apoptosis of oligodendrocytes in MS.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease
of the CNS. Most studies of disease progression in the white
matter of MS patients have focused on the autoimmune destruc-
tivemechanisms in CNS lesions. The identity andmechanisms of
processes generating disease progression and new lesions with
failures of remission and regeneration remain unknown (Mas-
tronardi and Moscarello, 2005). We previously proposed that
myelin damage inMSwhitematter results from a failure tomain-
tain compact adult myelin reflecting abnormally enhanced cit-
rullination of myelin basic protein (MBP), because these less cat-
ionic MBP isomers are unable to stabilize myelin multilayers
(Moscarello et al., 1994) and are more susceptible to digestion by
proteases (Pritzker et al., 2000).
Protein deimination (arginine to citrulline conversion) is me-
diated by a family of enzymes, the peptidylarginine deiminases
(PADs) (EC 3.5.3.15), that display both tissue and substrate spec-
ificity. The PAD genes are clustered on chromosome 1 in humans
(1p36.1) and syntenic regions of rodent genomes (Vossenaar et
al., 2003). The main PAD enzyme expressed in the CNS is PAD2.
It is found in white matter (Lamensa and Moscarello, 1993) and
oligodendrocytes (Akiyama et al., 1999) in which it deiminates
MBP (Wood and Moscarello, 1989; Lamensa and Moscarello,
1993) at abnormally high levels (Moscarello et al., 1994;Wood et
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al., 1996; Kim et al., 2003). PAD4, unlike other PADs, can trans-
locate into the nucleus (Vossenaar et al., 2003), in which it deimi-
nates histones (Hagiwara et al., 2002; Nakashima et al., 2002;
Cuthbert et al., 2004; Sarmento et al., 2004; Wang et al., 2004).
The association of PAD4 activity with a number of inflammatory
diseases (Nissinen et al., 2003; Lundberg et al., 2005; Makrygian-
nakis et al., 2006) may be an indicator of the involvement of this
enzyme in cellular stress mechanisms.
Here we show that PAD4 is overexpressed and activated in the
CNS of MS patients and animal models of demyelinating dis-
eases. PAD4 translocation into the nucleus stimulated by tumor
necrosis factor (TNF)- deiminated histone (H3) in normal-
appearing white matter (NAWM) of MS patients suggests a cas-
cade that may lead to increased oligodendrocyte apoptosis. The
present report on PAD4 proposes that multiple members of the
PAD family may be upregulated in MS tissue, each of which
contributes to the pathogenesis of MS in a particular manner.
Materials andMethods
Brain samples and fractionation. NAWM samples from brains of MS
patients and white matter from controls were obtained from the MS
tissue bank at the University of California, Los Angeles (F.G.M. and
P.C.-B.). The samples did not contain plaque material, and each one of
themwas accompanied by photographic documentation of the dissected
area. The clinical diagnosis, pathology, and autolysis times for the frozen
whitematter samples are summarized in supplemental Table 1 (available
at www.jneurosci.org as supplemental material). Fractionation of brain
samples into myelin (A and B), microsomal (C), and nuclear (D) frac-
tions fromwhitematter was performedwith amodification of a previous
method (Cruz and Moscarello, 1985) by differential centrifugation as
described previously (Mastronardi et al., 2000).
Transgenic mice.ND4 transgenic mice have been described previously
(Mastronardi et al., 1993, 1996; Moscarello et al., 2002). They contain 70
copies of the cDNA for the myelin-associated proteolipid protein (PLP)
DM20. Both the TGK21 and TG6074 TNF- transgenic mouse lines are
models for primary progressive demyelination as described previously
(Akassoglou et al., 1997, 1998, 1999). Mice used in this study had been
backcrossed into the C57BL/6 genetic background for at least seven gen-
erations. Brain nuclear and membrane-containing fractions were pre-
pared from normal and transgenic littermate mice as described previ-
ously for normal mice (Mastronardi et al., 2000). Animal use protocols
and studies were approved by the Animal Care Committee of The Hos-
pital for Sick Children.
Antibodies. Primary antibodies (Abs) used in this study included anti-
TNF- (Ab 1793), anti-histone H3 (Ab 1791), anti-citrullinated histone
H3 (anti-H3cit) (Ab 5103), all purchased fromAbcam(Cambridge,MA).
Antibodies against GFAP, CD3, CD8, and CD68 were purchased from
DakoCytomation (Glostrup, Denmark). The polyclonal antibody to
PAD isozymes (1–4)was a gift fromDr.H. Takahara (Ibaraki University,
Ibaraki, Japan). This antibody cross reacts with PAD1–PAD4 (Takahara
et al., 1989; Terakawa et al., 1991; Nishijyo et al., 1997; Rus’d et al., 1999).
The affinity-purified isotype-specific anti-PAD4 polyclonal antibody
was described previously (Vossenaar et al., 2004). Anti-citrulline IgM
mouse monoclonal antibody F95 (mAb F95) was a gift from Dr. A.
Nicholas (University of Alabama at Birmingham, Birmingham, AL).
Anti-citrulline (modified) detection kit was purchased fromUpstate Bio-
technology (Lake Placid,NY). Secondary anti-mouse and anti-rabbit IgG
heavy and light chain antibodies, conjugated with horseradish peroxi-
dase (Bio-Rad, Hercules, CA), were used inWestern and slot blot assays.
Immunohistochemistry. Immunohistochemistry of Formalin-fixed
paraffin-embedded non-neurological control white matter and MS
NAWM using anti-citrulline antibody (mAb F95) (Nicholas and Whi-
taker, 2002; Nicholas et al., 2005) was done according to the methods
described previously (Liu et al., 2005; Nicholas et al., 2005). Immunohis-
tochemistry using anti-GFAP, CD3, CD8, and CD68 antibodies for de-
tection of astrocytes, lymphocytes, and activatedmicroglia/macrophages
was done with an automated Ventana Medical Systems (Tucson, AZ)
Benchmark XT immunostaining system as performed by The Hospital
for Sick Children Immunopathology Service laboratory using their stan-
dard operating protocols for these reagents. Luxol fast blue (LFB) histol-
ogy was performed by The Hospital for Sick Children Pathology Service
laboratory.
Western blots and immunoslot blot quantitation.The identity of histone
H3 and histoneH3 citrullinated proteins was done byWestern blot anal-
ysis (Towbin et al., 1979). One polyclonal antibody recognized histone
H3, and the other recognized histone H3 in which arginines 2, 8, and 17
were deiminated. The detection of PAD4 was obtained by Western blot
analysis using an antibody generated against PAD4 (Vossenaar et al.,
2004) (1:100 dilution). TNF- antibody (Ab 1793) was used at a dilution
of 1:1000. Ab 1793 was made against full-length native purified human
TNF-. For slot blot analysis, these antibodies were diluted 1:2000
(mouse monoclonal anti-CD68), 1:4000 (rabbit polyclonals anti-CD3
and anti-CD8), and 1:10,000 (rabbit polyclonal anti-GFAP) and incu-
bated with humanwhitematter homogenate, 5g of protein per slot. All
primary and secondary antibodies were diluted in 5% nonfat dry skim
milk in Tris-HCl, pH 7.5 (blotto), containing 0.05% Tween 20. Immu-
noreactive bands were identified with horseradish peroxidase-
conjugated secondary antibodies followed by Enhanced chemilumines-
cence (ECL) detection (Amersham Biosciences, Piscataway, NJ) after
exposure of Kodak BiomaxXAR film (EastmanKodak,NewHaven, CT).
For Western blots, nuclear protein extracts from MS and normal mice
were prepared from nuclei isolated from frozen NAWM and whole-cell
extracts of cultured cells. Proteins were separated through 10–20%
tricine polyacrylamide gels (Invitrogen, Carlsbad, CA) by electrophoresis
and Western blotted onto nitrocellulose membranes. The membranes
were incubated with primary and secondary antibodies. The horseradish
peroxidase-linked secondary antibodies were detected using ECL sub-
strate and exposure of XAR Biomax Kodak film (Eastman Kodak).
To obtain the ratio of H3cit/H3, nuclear fractions containing 5 g of
protein diluted to 100ng/ml proteinwere loaded in triplicate ontowetted
nitrocellulose membranes in a Biodot (slot format) ultrafiltration unit
(Bio-Rad) under vacuum. The ratio of H3cit/H3 was calculated from
immunoslot blots after detection of H3cit and H3. The nuclear fractions
(D) diluted in PBS, pH 7.4, and 3 M urea were loaded onto slots in
triplicate.
Determination of the ratio of H3cit/H3 in mouse brain nuclear frac-
tions was done in a similar manner to that of the human (above). Quan-
titation of PAD4 in nuclear protein extracts was by an immunoslot blot
method. The antigens were measured in 10 g aliquots of total protein
applied to each slot. The assays for each individual were repeated three
times.
Acute and chronic experimental autoimmune encephalomyelitis. SJL
mice were purchased from Charles River (Montreal, Quebec, Canada),
certified pathogen free, and maintained in a pathogen-free environment
for 1–4 weeks before the start of experiments. Acute (aEAE) and chronic
relapsing (CREAE) experimental autoimmune encephalomyelitis was
induced in 6- to 8-week-old SJL femalemice as described previously by us
(Mastronardi et al., 2004). For induction of aEAE, 6- to 8-week-old SJL
females were injected subcutaneously at the base of the tail with bovine
MBP (200 g), emulsified in complete Freund’s adjuvant (CFA) (Difco,
Detroit, MI). Pertussis toxin (200 ng; Sigma, St. Louis, MO) was diluted
in PBS and injected intravenously via the tail vein. All mice were given a
second intravenous injection of pertussis toxin 48 h later. For chronic
relapsing EAE, mice were injected twice with proteolipid protein peptide
139–151 (HCLGKWLGHPDKF, 300 g emulsified in CFA) subcutane-
ously. Animal use protocols and studies were approved by the Animal
Care Committee of The Hospital for Sick Children.
Oli-Neu cell culture and treatments. Oli-Neu cells (a proliferating, un-
differentiated, murine oligodendrocyte progenitor cell line) were differ-
entiated in oligodendrocyte differentiation medium (ODM) containing
0.5 mg/ml cAMP for 7 d (medium was changed every 2 d). After 7 d in
ODM, cells were treated with 200 ng/ml TNF- recombinant protein for
different times (0, 1, 6, 24, and 48 h). The concentration of TNF- was
based on the consideration that these concentrations bestmimic a patho-
logical condition similar to the one present in vivo. In addition, the use of
this concentration for treatments of oligodendrocyte-derived cell cul-
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tures and primary oligodendrocytes has been documented by several
previous studies (Hisahara et al., 1997; Ladiwala et al., 1999; Ye and
D’Ercole, 1999; Cammer, 2000; Buntinx et al., 2004b). The cells were
harvested by trypsinization, and the cells that could not be trypsinized
were scraped off in cold PBS containing proteinase inhibitormixture. For
quantitation of PAD4 and H3cit/H3 ratios, cells were homogenized in
PBS, pH 7.4, in 3 M urea, diluted to a final protein concentration of 0.1
mg/ml, and aliquots corresponding to 5 g (H3 and H3cit) and 10 g
(PAD4) of total protein by an immunoslot blot method.
Transfection of Oli-Neu cells with PAD4 cDNA. Cells were plated at a
density of 1.4 105 cells/100mmdish in 7ml ofmedium containing 1%
horse serum and then transfected with 2 g of endotoxin-free pcDNA
expressing PAD4 or with empty vector control using Fugene 6 at a ratio
of 3l to 2g ofDNA.Cultureswere kept for 2 additional days in growth
medium and then either harvested or switched to differentiation me-
dium. Extracts were generated either 1 or 4 d later. Immunofluorescent
labeling of Oli-Neu cells was done by the method described by Liu et al.
(2005). The primary affinity-purified anti-PAD4 rabbit antibody was
detected with an anti-rabbit red fluorophore. Nuclei were labeled with
4,6-diamidino-2-phenylindole (DAPI). Immunoreactive cells were an-
alyzed using a fluorescence microscope (DM-RA; Leica, Nussloch, Ger-
many), and the images were captured using a Hamamatsu (Shizouka,
Japan) CCD camera interfaced with a G4 computer.
Statistical analysis. Data were analyzed with two-tailed parametric
tests, and end points were compared by Fisher’s exact test. Significance
was set at 5%. Results of image analysis were analyzed by Tukey–Kramer
multiple comparison tests. MS and the normal groups were compared
using nonparametric two-tailed p value unpaired t tests with the Mann–
Whitney test using Prism and Instat software (GraphPad Software, San
Diego, CA) for the Power Mac.
Results
In this study, we analyzed NAWM tissue from MS brains and
whitematter from control patients to define biochemical changes
that would render these regions more susceptible to subsequent
lesion development.NAWMhas been demonstrated to be abnor-
mal because of several biological and histological changes and is a
site of active pathology. It may represent early stages preceding
demyelination. A discussion of these changes has been published
by Ludwin (2006).
PAD4 is elevated inMS normal-appearing white matter
Citrullination is an irreversible, posttranslationalmodification of
arginine residues in proteins.We have shown previously that this
modification occurs on MBP from white matter of both normal
and MS tissues (Moscarello et al., 1994; Kim et al., 2003), and it
becomes pronounced as the disease progresses, with acute fulmi-
natingMarburg’s disease themost extreme example (Wood et al.,
1996).
Because immunohistochemical PAD staining revealed an ele-
vated nuclear localization of PAD in theMS compared with con-
trol sections (data not shown),we decided to further analyze PAD
subcellular localization after fractionation of NAWM samples
fromMS patients and control brains.Whitematter samples from
normal and MS were thereby fractionated using previously pub-
lished methods (Mastronardi et al., 2000) into the following: a
membrane-containing fraction (arbitrarily denominatedAB),
which contains myelin, a non-myelin microsomal fraction
(called C), and a nuclear fraction (called D). Quantitation of the
relative amount of binding of the anti-PAD (1–4) antibody in the
normal andMS fractions (Fig. 1A) revealed high levels in theMS
myelin fractions (A B). The C fraction contained the smallest
amount, but it was still 2.8-fold higher in patients than in the
normal C fraction. Interestingly, the nuclear fraction (D) con-
tained a 3.5-fold higher level of PAD1–PAD4 in the MS samples
compared with normal controls, and this was most likely attrib-
utable to the nuclear PAD4 protein. Because PAD1 is found
mainly in the epidermis and uterus and PAD3 in hair follicles,
these observations implicated elevation of two PAD activities:
PAD2, known to preferentially deiminate (or citrullinate) MBP
(Lamensa and Moscarello, 1993), and nuclear PAD4, known to
preferentially deiminate nucleosomal histones (Cuthbert et al.,
2004; Wang et al., 2004).
To determine whether PAD4was elevated in nuclear fractions
from normal white matter and MS NAWM, we probed Western
blots with anti-PAD4 antibody, which showed elevated but vari-
able PAD4 levels in MS samples (Fig. 1B). These results are in-
dicative that a nuclear PAD4 was expressed and elevated in MS
NAWM.
Citrullinated histone H3 in NAWM from MS
To determine whether elevated nuclear PAD4 was accompanied
by citrullination of nuclear proteins, we used a citrulline-specific
monoclonal antibody (F95) to stain normal (Fig. 2A) and MS
(Fig. 2B,C) white matter sections. The F95 staining revealed
strong nuclear labeling in the MS white matter, which was less
and more diffuse in the normal white matter. The increased nu-
clear labeling, as shown in the higher magnification (1000 oil)
(Fig. 2C, arrows) with the anti-citrullinemonoclonal antibody in
the MS nuclei, was likely the result of elevated nuclear PAD4.
To substantiate that histone H3 was citrullinated, we mea-
sured citrullinated histone H3 directly with anti-histone H3 an-
tibody (anti-H3cit) preparedwith a synthetic peptide recognizing
the citrullinated sites shown in Figure 2D. We prepared nuclear
protein fractions from various frozen normal white matter and
NAWM of MS individuals to determine whether H3cit was ele-
Figure 1. PAD4 in normal white matter and MS normal-appearing white matter. A, The
differential distribution of PAD (1–4) proteins inMS sampleswas confirmed by fractionation of
brain extracts intomembrane (AB),microsomal (C), andnuclear (D) fractions. Theamountof
total PAD protein was measured, and the results are presented as a bar graph of values in MS
samples relative to normal controls.B, Anti-PAD4Western blot of nuclear fraction from cortical
white matter further supported the increased levels of PAD4 in the nuclear fraction of MS
sample compared with the levels in normal controls. The nuclear fractions used in the PAD4
Westernblotwere as follows:Normal 1, 2, and3areHSB3236, 3276, and3322;MS4–9areHSB
3502, 2429, 3522, 3509, 2800, and2485, respectively. These individuals are described further in
supplemental Table 1 (available at www.jneurosci.org as supplemental material).
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vated in theMS cases. AbundantH3cit was present inMSNAWM
nuclear fractions as detected by Western blot, with only traces in
white matter from controls (Fig. 2E). Based on these results, we
calculated the ratio of H3cit/H3 in the nuclear fractions prepared
from a number of individuals with MS and normal controls by
immunoslot blot. The scatter plot shown in Figure 2F revealed a
variable but elevated clustering of H3cit/H3 ratios for the MS
group. These ratios ranged fromvery high proportions ofH3cit to
moderate ratios,0.3. The normal individuals had H3cit/H3 ra-
tios significantly below the MS ratios. The mean of the H3cit/H3
ratio for all of theMS individuals, as a group, was 0.6. That of the
normal group was 0.2. The nonparametric comparison of the
means of the MS group and the normal showed a significant
difference, with a p value 0.01. These results suggest that the
increased nuclear PAD4 in MS NAWM was associated with in-
creased levels of citrullinated histone H3.
TNF- in NAWM fromMS patients
To determinewhether the proinflammatory cytokine TNF-, the
overexpression of which induced demyelinating disease in mice
(Akassoglou et al., 1999), was also elevated in MS, we quantified
the amount of TNF- in white matter from normal individuals
and NAWM from MS patients (n  17 MS; n  8 normal).
Quantitation of the amount of TNF- for theMS group revealed
a 2.4-fold increase ( p 0.0001) of TNF- inNAWM(Fig. 3A). A
possible source for TNF- in the MS NAWM might be from
inflammatory cells, such as infiltrating macrophages and/or res-
identmicroglia and activated astrocytes or a combination of all of
these cell types. To determine whether any of these cells were
involved, we used various cytological markers of inflammatory
infiltrates to determine whether an underlying inflammation was
present inMSNAWMsamples. The following specific cytological
markers were used: anti- GFAP to measure astrocytosis, anti-
CD68 to measure microglia and/or macrophage (Ulvestad et al.,
1994), and anti-CD3 (Selmaj et al., 1991) and CD8 (McDole et
al., 2006) to measure lymphocyte infiltration. The results for
these markers are shown in Figure 3B and revealed similar levels
of CD3, CD8, and CD68 between MS and normal individuals.
Only GFAP levels were significantly elevated (1.5-fold) in MS
samples compared with controls ( p 0.0001). These biochem-
ical results were further substantiated by immunohistochemical
analysis (supplemental Figs. 2, 3, available at www.jneurosci.org
as supplemental material). Briefly, LFB staining was done to en-
sure that the quality of the Formalin-fixed MS and normal white
matter tissue sections were comparable and that the MS NAWM
lacked detectable lesions (supplemental Fig. 1, available at www.
jneurosci.org as supplemental material). Immunohistochemical
analysis of white matter tissue sections revealed a variable but
consistent astrocytosis (as determined by GFAP staining) in the
MS NAWM sections compared with normal controls (supple-
mental Fig. 2, Table 2, available at www.jneurosci.org as supple-
mental material). CD68, to assess microglial infiltration, was
barely detectable (supplemental Fig. 2, available at www.jneurosci.
org as supplemental material). CD3 and CD8 stainings, to assess
lymphocytic infiltration also revealed no differences between the
normal and MS white matter (supplemental Fig. 3, available at
www.jneurosci.org as supplemental material). Together, these
results suggest that the main contribution of TNF- in these MS
cortical NAWM samples may be from astrocytes.
Figure 2. Citrullinated histones in normal and MS brain and nuclear fractions. Immunohis-
tochemical staining of normal (A, 400), andMS (B, 400; C, 1000 oil) white matter with
anti-citrulline (F95) monoclonal antibody. Arrows indicate nuclear labeling with the F95 anti-
body. Amore intense nuclear labelingwas observed in theMSwhitematter.D, The sequence of
the tri-citrullinated N-terminal histone H3 peptide in which the arginyl residues at positions 2,
8, and 17 are replaced by citrulline. E, Western immunoblot of nuclear fractions prepared from
white matter from normal and MS individuals with anti-histone H3 and anti-H3 cit. F, The
ratio SD of H3 cit/H3 in nuclear white matter fractions from normal and individuals with MS.
Themeanof theH3 cit/H3 ratios for theMSandnormalgroups is indicatedby thehorizontal lines
( p 0.01, nonparametric test). A list of the clinical diagnosis for each of the samples used in
these experiments and the values SD of the H3 cit/H3 ratios are provided in supplemental
Table 1 (available at www.jneurosci.org as supplemental material).
Figure 3. TNF- and cytological markers in MS NAWM. A, Quantitation of TNF- SD in
white matter from normal (N) (n 8) and NAWM fromMS patients (n 17) by immunoslot
blot. B, Quantitation SD of GFAP, CD3, CD8, and CD68 levels in normal (N) white matter and
MS NAWM. C, Relative amount of PAD4 SD in brain nuclear fractions from SJL, aEAE, and
CREAE mice. D, Western blot of whole-brain proteins from SJL, aEAE, and CREAE mice with
anti-GFAP, anti-TNF-, anti-histone H3 cit, and anti-histone H3. E, Amount of TNF- SD
( p 0.001) in 5g of total brain proteins from SJL, aEAE, and CREAE mice.
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TNF- and PAD4 in EAE
EAE is a T-cell-mediated disease that displays many of the
immune-mediated changes found in MS. Because these mole-
cules (CD3, CD8, andCD68) are elevated in EAE as a result of the
cellular infiltration, they may contribute additional TNF-. To
determine whether there were changes in PAD4 protein levels in
nuclear fractions prepared from aEAE and CREAE after disease
induction, we used the anti-PAD4 antibody in immunoslot blot
assays. Pooled data from untreated SJL mice and animals with
aEAE induced withMBP and CREAE induced with PLP (peptide
139–151) both had a 1.5-fold increase of PAD4 compared with
the control group (Fig. 3C). To determine whether the PAD4
increase was associated with TNF-, we used the anti-TNF-
antibody in aWestern blot of whole-brain extracts prepared from
SJL, aEAE, and CREAEmice. The results showed that TNF-was
elevated in both the aEAE andCREAEmodels (Fig. 3D).Western
blot of GFAP revealed an increase of GFAP in both aEAE and
CREAE (Fig. 3D). The increase in GFAP was consistent with
astrocytosis, also a feature of EAE (Mastronardi et al., 2004).
Western blot analysis of H3 and H3cit revealed a significant in-
crease in the proportion ofH3cit in theCREAEbrain, whereas the
total histone H3 (H3cit  H3) was similar in SJL, aEAE, and
CREAE (Fig. 3D). The proportion ofH3cit inH3was only slightly
increased in the aEAE brain.
To determine whether TNF-was elevated in the EAE brains,
wemeasured TNF- by immunoslot blot of whole-brain homog-
enates and used H3 levels to account for protein loading. The
results revealed a very significant ( p 0.001) elevation of TNF-
in the CREAE brain by fivefold over SJL. The level of TNF- in
CREAE was also significantly above that of the aEAE ( p 0.05)
by 1.25-fold (Fig. 3E). These results suggest that TNF-may have
been contributed by multiple cellular infiltrates. The EAE results
revealed an association betweenhighTNF- and elevated nuclear
PAD4 and H3cit.
Nuclear PAD4 and TNF- are increased before clinical
disease in a primary progressive demyelinating mouse model
To address early events before the onset of demyelination in
NAWM, we used the ND4 transgenic mouse model. These mice
have been described previously (Mastronardi et al., 1993, 1996;
Moscarello et al., 2002). They have a normal period of develop-
ment up to 3 months after birth and thereafter develop a chronic
progressive primary CNS demyelination. Western blots of ND4
nuclear brain extracts revealed constant PAD4 expression in nu-
clear fractions of nontransgenic littermate mice but a dramatic
rise of nuclear PAD4 with preclinical disease (3 months) (Fig.
4A). The readout for the activity of nuclear PAD4 was deter-
mined by quantitating the amount of histone H3cit, which is
represented as a ratio of H3cit/H3 in normal and ND4 mouse
brain nuclear extracts from mice between 2 and 8 months of age
(Fig. 4B). At 2 months of age, the ND4 had a similar ratio to the
normal. The ND4 ratio increased 2.5-fold at 3 months (preclini-
cal 3 clinical). The high ratio was sustained throughout the
course of the disease, demonstrating that the increased nuclear
PAD4 was observed before the onset and persisted during demy-
elinating disease.
TNF- expression in total brain extracts of ND4 mice at 2, 3,
6, and 8months of age was determined byWestern blot (Fig. 4C).
Scanning the Western blot and calculating the ratio of TNF-/
histone H3 revealed that the levels in the ND4 were elevated at all
ages compared with the nontransgenic littermates. The ratios for
TNF-/H3 in the normal mouse from 2 months 3 8 months
increased from 0.06 to 0.6. In theND4mouse, TNF-/H3 ratio at
2 months was 0.6. At 8 months, the ratio increased to 2.1. These
results revealed that TNF- at 2 months was elevated 10- and
4-fold at 3 months in the ND4 mouse, before clinical signs of
demyelination. The increased levels of TNF- and the accumu-
lation of nuclear PAD4 and H3cit implied an association with
disease development in the ND4 transgenic mouse.
Mechanism of translocation of PAD4 into the nucleus
PAD4 expression was analyzed in a proliferating, undifferenti-
ated, murine oligodendrocyte progenitor cell line, Oli-Neu
(Scholze et al., 1996;Gokhan et al., 2005), to elucidate someof the
factors involved in the translocation of PAD4. Immunofluores-
cence showed a predominantly cytoplasmic enzyme distribution
and a small amount of nuclear labeling (Fig. 5A, red fluorophore
label). After differentiation of the cells for either 1 d (Fig. 5B) or
Figure 4. Nuclear PAD4 protein and TNF- in ND4 brain.A, Western blot with an anti-PAD4
polyclonal antibody of nuclear fractions prepared from2-, 3-, and6-month-oldND4andnormal
littermates. Histone H3 immunoreactivity was used as a loading control.B, Nuclear PAD4 activ-
itywasmeasured by determining theH3 cit/H3 ratio inND4brains relative to normal littermates
from 2–8 months SD. C, TNF- Western blot of whole-brain protein homogenates from
normal and ND4 littermates at 2, 3, 6, and 8 months of age. Histone H3 immunoreactivity was
used as a loading control.
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5 d (Fig. 5C) (Gokhan et al., 2005), the
localization of PAD4 was still mainly cyto-
plasmic, suggesting that nuclear transloca-
tion of the enzyme is not part of the con-
stitutive differentiation program but may
require exogenous signals. We considered
the following.
Overexpression of PAD4
Because PAD4 levels were elevated in MS
patients, we asked whether overexpression
of PAD4 by itself would be sufficient for
nuclear localization. Oli-Neu cells were
transiently transfected with PAD4 cDNA,
and nuclear enzymatic activity was mea-
sured by the formation of H3cit in undif-
ferentiated and differentiated cells using
the anti-H3cit antibody. Cellular levels of
the enzyme were assessed in protein ex-
tracts from PAD4-transfected and un-
transfected cells by Western blot analysis
(Fig. 5D). Immature proliferating cells
contained PAD4 protein (lane 1), and
transfection predictably increased PAD4
levels (lane 2). Enzymatic activity on nu-
clear histone was also indirectly assessed in
the transfected and untransfected cells by
comparing the levels of H3cit with actin.
Because the level of H3cit was unchanged,
overexpression of PAD4 alonewas not suf-
ficient for the translocation to the nucleus.
Similar results were obtained in differenti-
ated Oli-Neu cells (lanes 3, 4) although
transfection efficiency was less. We con-
cluded that increased cytosolic PAD4 ex-
pression is not sufficient to induce nuclear
translocation but requires additional fac-
tors, e.g., TNF-.
TNF- signals PAD4 nuclear translocation
in oligodendrocyte cell lines
Given the importance of TNF- in demy-
elinating disorders (Akassoglou et al., 1997,
1998, 1999), we reasoned that TNF- could
have an important role in the transloca-
tion of PAD4 into the nucleus of oligoden-
drocytes, resulting in histone deimination.
TNF- treatment of Oli-Neu cells caused
PAD4 to shift from a uniform cytoplasmic
distribution (red label) with hardly any de-
tectible PAD4 label in nuclei before TNF-
treatment (Fig. 5E). Nuclei were counter-
stained blue with DAPI to identify this
compartment. After exposure of Oli-Neu
cells with TNF- for 30 min, a prominent
redistribution of PAD4 into a vesicular
compartment was found as determined by
the presence of vesicular staining in the cy-
toplasm (Fig. 5F). After 60 min of TNF- exposure, PAD4 was
predominantly found in Oli-Neu nuclei (Fig. 5G, arrowheads).
Nuclear PAD4 persisted after 24 and 48 h of continuous exposure
to TNF- (Fig. 5H, I). Besides the redistribution of PAD4 after
TNF- exposure, we also found that the levels of PAD4 pro-
tein increased. This was evident by the increased cytoplasmic
staining of PAD4 in Figure 5, H and I, and by quantitation of
PAD4 in Oli-Neu whole-cell extracts (Fig. 5J ). Nuclear PAD4
activity readouts in the Oli-Neu cells was assessed by the ratio
of H3 cit/H3. This was also increased by TNF- exposure after
1 h and then increased more slowly to a maximum amount by
24–48 h (Fig. 5K ).
Figure 5. PAD4 subcellular localization in the Oli-Neu oligodendrocyte cell line. A, PAD4 subcellular localization in immature
Oli-Neu cells during growth revealed it to be cytosolic. B, Oli-Neu cells 1 d in differentiation media. C, Oli-Neu cells 5 d in
differentiationmedia. The rectangle is an areamagnified inE.D, PAD4Western blot of cell extracts fromproliferatingOli-Neu cells
transfected with pcDNA plasmid (lane 1) and proliferating Oli-Neu cells transfected with mouse PAD4 cDNA in a pcDNA plasmid
(lane 2). Differentiating cells transfectedwith pcDNAplasmid (lane 3) anddifferentiating cells transfectedwithmousePAD4 cDNA
in a pcDNA-plasmid (lane 4) are shown. H3 cit Western blot of whole-cell extracts from proliferating Oli-Neu cells (lanes 1, 2) and
differentiating Oli-Neu cells (lanes 3, 4) is shown. Actin was used as a loading control in the Western blot. E, Oli-Neu cells (0 min
TNF- exposure). PAD4was labeledwith red fluorescence. Nuclei were labeledwith DAPI (blue fluorescent label). F, Oli-Neu cells
stained for PAD4 (red label) and nuclei with DAPI (blue label) after 30 min TNF- exposure. G, PAD4 translocated into nuclei
indicated by arrowheads after 60min TNF- exposure.H, I, PAD4 persisted in Oli-Neu nuclei (arrowheads) after 24 h (H ) and 48 h
( I). Scale bar, 50m. J, K, Quantitation of the relative amount of PAD4 (J ) and the ratio of H3 cit/H3 in Oli-Neu cells exposed to
TNF- after 0, 1, 6, 24, and 48 h (K ). Each time pointwas assayed 12 times SD except the 6 and 48 h times,whichwere assayed
six times SD. The p values for both PAD4 levels and the H3 cit/H3 ratios were for the 0 and 24 h after TNF- exposure. L,
Quantitation of the ratio of H3 cit/H3 SD ( p 0.001) in MO3-13 human oligodendrocytes exposed to recombinant human
TNF- for 24 h.
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To determine whether a similar effect could be elicited on a
human oligodendrocyte cell line, we exposed differentiated
MO3-13 cells (McLaurin et al., 1995) with human recombinant
TNF- for 24 h and then measured histone H3cit/H3 ratios. The
results shown in Figure 5L revealed that human TNF- was able
to elicit a significant 1.67-fold ( p 0.001) increase in H3cit/H3
ratio. The data from both differentiated Oli-Neu and MO3-13
cells are indicative that exposure to TNF- can affect nuclear
targeting of PAD4 and subsequent generation of H3cit.
Nuclear PAD4 is elevated in brains from TNF- transgenic mice
Transgenic mice that have CNS-specific overexpression of a mu-
rine TNF- transgene (the Tg6074 line) or astrocyte-targeted
expression of a tethered transmembrane human TNF- ligand
(the TgK21 line) (Akassoglou et al., 1999) were used to determine
whether elevated TNF- affected PAD4 nuclear activity directly.
Both the TGK21 and TG6074 TNF- transgenic mouse lines un-
dergo a preclinical phase inwhich they are indistinguishable from
nontransgenic littermates and thereafter show neurological signs
of primary progressive demyelination (Akassoglou et al., 1999).
The TGK21 line is preclinical at 2 weeks and displays severe
symptoms of demyelination by 4 weeks. The TG6074 line is nor-
mal up to 4 weeks and shows signs of severe demyelination by 6
weeks. To confirm that these mice overexpress TNF- protein,
wemeasuredTNF-using the anti-TNF- antibody (Ab 1793) in
a slot blot assay of whole-brain homogenates. The results shown
in Figure 6A revealed a significant increase of TNF- in the pre-
clinical and clinical phases of both TGK21 and TG6074 mice
( p  0.001) compared with nontransgenic littermates. There-
fore, to address the question whether PAD4 was elevated in nu-
clear fractions before clinical signs and during disease progres-
sion, we analyzed PAD4 levels in nuclear fractions from these
mice and compared them with their nontransgenic littermates.
We found that the levels of nuclear PAD4 was elevated in both
preclinical and clinical phases of disease correlatedwith increased
expression of the transgene (Fig. 6B), with mean levels for both
lines being 1.8 0.4-fold higher than nontransgenic littermates.
As a group, the TNF- transgenic mice had an H3cit/H3 ratio of
0.47  0.01 compared with 0.24  0.01 for the littermates (Fig.
6C). These data suggest that TNF- has a role in the translocation
of PAD4 into the nucleus from the cytoplasm.
Discussion
Higher-order protein structures induced by posttranslational
modifications are often associatedwith reversible events involved
in signal transduction. Many modifications, however, are not
reversible and invoke new primary structures not encoded by the
genome.One of thesemodifications, deimination of proteins, the
conversion of positively charged arginine to a neutral citrulline, is
recently gaining more prominence as an activator and indicator
of autoimmune disease (Vossenaar et al., 2003).
The failure to remyelinate involves not only early develop-
mental molecules (John et al., 2002; Mastronardi et al., 2003,
2004; Mastronardi and Moscarello, 2005) but also an intracellu-
lar PAD (PAD4), which deiminates histones in oligodendrocytes.
We demonstrate here that PAD4 levels and activity are elevated in
NAWMofMS patients.We further show that PAD4 accumulates
in the nuclei of cells in the white matter, in which it catalyzes the
conversion of arginine to citrulline in the tail of nucleosomal
histones, thereby affecting the integrity of histone–chromatin
interactions.Higher-order genomicDNA structure and gene reg-
ulation is controlled by histone proteins. Histones are highly ba-
sic nuclear proteins that are subject to posttranslational modifi-
cations that can be reversible. These include acetylation,
deacetylation, and methylation of N-terminal lysine residues
(Roth and Allis, 1996; Svaren and Horz, 1996; Zhang and Rein-
berg, 2001). Deimination of arginine residues on histones are
irreversiblemodifications that alter their net positive charge. As a
result, deiminated histones have altered intermolecular interac-
tions with proteins and likely with DNA (Sarmento et al., 2004).
Because changes in the secondary structure of nucleosomal his-
Figure 6. Nuclear PAD4 and TNF- in TGK21and TG6074 brains.A, Quantitation of TNF- in
whole-brain homogenates from TGK21 (), TG6074 (), and nontransgenic littermates ()
from2-week-old TGK21 (preclinical), 4-week-old TGK21 (clinical), 4-week-old TG6074 (preclin-
ical), and 6-week-old TG6074 (clinical)mice ( p0.001).B, Relative PAD4 levels in TGK21 ()
and TG6074 () transgenic mouse brains compared with nontransgenic () littermates at 2,
4, and 6 weeks of age. C, Ratios of nuclear citrullinated proteins/H3 SD in brain nuclear
protein extracts from individual TGK21 () and TG6074 () transgenic mice compared with
nontransgenic littermates (). The means of the H3 cit/H3 ratios for the TGK21and TG6074
transgenic mouse groups compared with their nontransgenic littermates are represented by
the horizontal lines ( p 0.001, nonparametric test).
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tones modulate cell-specific gene expression (Ensoli et al., 1999;
Brooks, 2005; Scalabrino, 2005), we propose that the increased
PAD4 nuclear activity could be part of either the demyelinating
process or part of a failed repair
In support of the idea that citrullinated histone affects the
chromatin structure in patients, we also found that HP1-, a
protein that has an important role in chromatin compaction
(Verschure et al., 2005), was decreased in NAWM from MS tis-
sue. Although the effects of these changes on differentiation are
not known, it has been shown that changes in the acetylation state
of histones affect the ability of oligodendrocyte progenitors to
differentiate into myelinating cells both in vitro and in vivo
(Marin-Husstege et al., 2002; Shen et al., 2005). In addition,
PAD4has been suggested to be a regulator of the pS2 promoter by
histone deimination, a promoter that responds to estrogen stim-
ulation (Wang et al., 2004; Denman, 2005; Kearney et al., 2005),
which in turn is suggested to be involved in many diseases, in-
cludingmultiple sclerosis. Deimination of arginine in histones by
PAD4 has been demonstrated in other cell types (Cuthbert et al.,
2004; Wang et al., 2004) to render the histones more susceptible
to degradation, as demonstrated for citrullinated MBP (Pritzker
et al., 2000; D’Souza et al., 2005). Together, the evidence is indic-
ative that changes in the secondary structure of histones attribut-
able to PAD4 translocation could either interfere with myelin
biosynthesis and remyelination or could affect cell survival.
The role of TNF- in PAD4 translocation was demonstrated
in vitro in the Oli-Neu oligodendrocyte cell line, because incuba-
tion of the cells with TNF-was shown to translocate PAD4 into
the nucleus within 1 h. This translocation of a protein involved in
regulating gene expression is reminiscent of several other pro-
teins, including a prototypical transcription factor, nuclear factor
B (NF-B), that dissociates from its partner I-B on TNF-
activation, exposing a nuclear localization signal and allowing
translocation of the protein to the nucleus (Fagerlund et al.,
2005). Our results with the overexpression of PAD4 in Oli-Neu
cells were indicative that overexpression was not sufficient to
target PAD4 into the nucleus. This suggests that, like NF-B,
PAD4 may be sequestered cytoplasmically, released, and then
targeted to the nucleus after a TNF- inductive signal.
Because of the role of TNF- in apoptosis of oligodendrocyte
cell lines (Buntinx et al., 2004a,b) inMS brain (Raine et al., 1998),
we propose here that PAD4 activity may affect oligodendrocyte
survival by inducing the progressive accumulation of deiminated
histones. If the histone deimination were kept unchecked, this
would lead to irreversible nuclear changes and finally apoptotic
death. In animal models of MS that spontaneously demyelinate,
such as transgenic ND4, TGK21, and TG6074 mice, both TNF-
and PAD4 were elevated before clinical disease. More impor-
tantly, nuclear PAD4was elevated in the transgenicmouse brains
before clinical signs of demyelination, suggesting that these mol-
ecules have important roles in the pathogenesis of demyelinating
diseases.
TNF- expression in transgenic mice has been shown to be
sufficient to induce non-immune-mediated demyelination
(Probert et al., 1995; Kassiotis et al., 1999). Because TNF- is
expressed by astrocytes and macrophages (Chung et al., 1991)
and because TNF- also promotes proliferation of astrocytes
(Selmaj et al., 1990), we propose the existence of a TNF- feed-
forward loop that would supposedly fuel the cycle of a persistent
inflammatory state and induce the nuclear translocation of PAD4
in oligodendrocytes.
The pathogenesis of MS is complex. Our studies have sug-
gested that the PAD enzymes, of which five are known, have
important roles in this disease. Of the five PAD enzymes, we have
shown that PAD2 is involved primarily with demyelination re-
sulting from the deimination of MBP. Although PAD4 is a cyto-
plasmic enzyme, it is translocated to the nucleus in which it de-
iminates histones, a process that is increased in MS patients.
Chromatin compaction is affected with subsequent disruption of
the biosynthetic machinery of the cell. Therefore, PAD4 appears
to be involved in epigenetic mechanisms in MS that may include
demyelination and failed remyelination. In this report, we
showed an association of increased PAD4 with increased H3cit
and TNF- in MS NAWM and in the brains of animal models of
demyelination. The mechanism involves translocation of PAD4
3 nucleus, which is mediated by TNF-. Overexpression of
PAD4 alone does not induce its translocation. Furthermore,
chronic TNF- exposure of oligodendrocyte cells in culture in-
duced increased PAD4protein. These studies suggest that nuclear
PAD4 contributes to the pathogenesis of MS and possibly other
inflammatory diseases involvingTNF- and histone deimination
(A. Suzuki et al., 2003; K. Suzuki et al., 2003).
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